January 28, 2014 | Israeli company Oramed Pharmaceuticals, which is developing a revolutionary insulin pill for diabetics, has filed a request to raise $100 million on Nasdaq. The company is already publicly traded and has shown a rise in stock since its report of a successful trial for its type 1 diabetes treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments